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Most cases of sporadic primary hyperparathyroidism present disturbances in a single parathyroid gland and the
surgery of choice is adenomectomy. Conversely, hyperparathyroidism associated with multiple endocrine neoplasia
type 1 (hyperparathyroidism/multiple endocrine neoplasia type 1) is an asynchronic, asymmetrical multiglandular
disease and it is surgically approached by either subtotal parathyroidectomy or total parathyroidectomy followed by
parathyroid auto-implant to the forearm. In skilful hands, the efficacy of both approaches is similar and both should
be complemented by prophylactic thymectomy. In a single academic center, 83 cases of hyperparathyroidism/
multiple endocrine neoplasia type 1 were operated on from 1987 to 2010 and our first surgical choice was total
parathyroidectomy followed by parathyroid auto-implant to the non-dominant forearm and, since 1997, associated
transcervical thymectomy to prevent thymic carcinoid. Overall, 40% of patients were given calcium replacement
(mean intake 1.6 g/day) during the first months after surgery, and this fell to 28% in patients with longer follow-up.
These findings indicate that several months may be needed in order to achieve a proper secretion by the
parathyroid auto-implant. Hyperparathyroidism recurrence was observed in up to 15% of cases several years after
the initial surgery. Thus, long-term follow-up is recommended for such cases. We conclude that, despite a tendency
to subtotal parathyroidectomy worldwide, total parathyroidectomy followed by parathyroid auto-implant is a valid
surgical option to treat hyperparathyroidism/multiple endocrine neoplasia type 1. Larger comparative systematic
studies are needed to define the best surgical approach to hyperparathyroidism/multiple endocrine neoplasia type
1.
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INTRODUCTION
Primary hyperparathyroidism (HPT) is highly prevalent
in patients with multiple endocrine neoplasia type 1
(MEN1), and its penetrance is almost complete by the age
of 40 years (1–7). HPT associated with MEN1 (HPT/MEN1)
is an asynchronic, asymmetric multiglandular and multi-
focal disorder; the vast majority of cases are benign tumors
and represented by parathyroid hyperplasia or adenoma
(8); it occurs equally in males and females, and it frequently
occurs at ages under 30 years (1,2). Despite relatively mild
elevations in serum parathormone (PTH) and total/ionized
calcium usually seen in HPT/MEN1, there have been recent
reports of early onset, and progressive, frequent, extensive
and severe bone and renal complications (7,9)
In recent years, routine genetic screening performed in at-
risk family members of index MEN1 cases has significantly
increased the recognition rate of young asymptomatic
patients presenting at early metabolic stages of HPT in our
and other institutions (10,11). Furthermore, in recent decades,
the clinical picture of sporadic or familial HPT has changed
dramatically and most cases are more frequently recognized
and diagnosed early, at asymptomatic stages (12,13).
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(S1):131-139 DOI:10.6061/clinics/2012(Sup01)22
131
Medical non-surgical strategies
The medical treatment of HPT associated with MEN1 is
still under investigation. The experience with cinacalcet in
HPT is limited to few cases, and no long-term follow-ups of
disease end-points are available, despite short-term (up to
24 weeks) reductions of calcium and PTH (14–16).
Also, the use of percutaneous ethanol injection in cases of
HPT recurrence after subtotal parathyroidectomy in HPT/
MEN1 patients resulted in short-term eucalcemia. However,
hypercalcemia recurred in 90% of cases after 32 months of
therapy (17).
Furthermore, high-intensity focused ultrasound applied
to sporadic, uniglandular HPT is under investigation,
although temporary palsy of the recurrent laryngeal nerve
in one out of four cases has been reported. Recovery was
noted only 40 days after therapy (18), and the role of high-
intensity focused ultrasound in multiglandular parathyroid
disease is yet to be defined.
Long-term annual clinical follow-up has been recom-
mended for selected sporadic cases of HPT, because bone
mineral density may remain stable up to 10 years after
diagnosis (19,20). To date, it is not clear whether this
recommendation can be extended to HPT/MEN1.
Surgical treatment
Surgery is the classic therapy for primary HPT in MEN1.
However, the criteria to indicate parathyroidectomy in these
cases remain under debate. The International Consortium/
National Institutes of Health Consensus on MENs (1)
recommended that indications for parathyroidectomy in
MEN1 should follow the same criteria used for sporadic
asymptomatic primary HPT (21,22).
Most HPT/MEN1 patients are younger than 50 years at
diagnosis, and thus fulfill the indication for parathyroid
surgery based solely on this criterion. However, it may not
be easy to convince an asymptomatic patient that he/she
will benefit from an operation that can be considered
palliative, as recurrence rates are usually high (23). In some
young asymptomatic cases, the treatment may be perceived
as worse than the disease itself (24).
Surgery in HPT/MEN1
The surgical treatment of HPT/MEN1 is a challenge to the
surgeon for several reasons. First, in the vast majority of cases,
HPT/MEN1 is a multiglandular disease that usually occurs
asymmetrically and asynchronically. Second, the frequency of
supernumerary parathyroid glands is considerable. Further-
more, the surgeon is frequently confronted with parathyroid
glands with macroscopic features resembling normal char-
acteristics and he/she must decide how much tissue should
be taken, evaluating the risk for permanent hypoparathyroid-
ism versus disease persistence or early recurrence. One
parathyroid gland may appear normal macroscopically, but
may cause persistent hypercalcemia (24). Finally, although
questionable as a 100% effective preventive strategy for
thymic carcinoid tumors (25,26), transcervical thymectomy
has been recommended to be carried out during parathyr-
oidectomy in HPT/MEN1 cases (27).
Presurgical diagnosis of MEN1
As the first manifestation of MEN1 is usually HPT, and
was found to increase .70% in one of our series (28),
clinicians and surgeons must be strictly committed to
making or ruling out a diagnosis of MEN1 before neck
exploration in each patient with apparently sporadic HPT.
An adequate preoperative diagnosis may help the surgeon
to choose the best surgical option (24,29,30). It is well
documented that measurement of intraoperative PTH may
fail in patients undergoing parathyroidectomy for whom
MEN1 is not suspected (31). Moreover, early diagnosis of
MEN1 is critical to the adequate management of other
MEN1-related tumors that have a clinical impact (3). In this
context, mutation analysis of the MEN1 gene in apparently
sporadic cases of HPT in which the patient is younger than
30 years of age may be helpful in the surgical management
of HPT (1).
Genetic testing is crucial to confirm the familial character
of HPT disease within clinically affected family members
identified in MEN1 kindreds genetically characterized by a
MEN1 germline mutation. Although rare, relatives pre-
senting primary HPT but not harboring a germline MEN1
mutation have been reported. According to MEN1 clinical
criteria, these patients would have been diagnosed as a
MEN1 affected case (1). However, they are classified as
sporadic HPT cases and should be surgically treated
accordingly. Such cases represent MEN1 phenocopies,
and do not need further surveillance for MEN1-related
neoplasias.
Parathyroid hyperplasia or adenoma accounts for the vast
majority of HPT cases in MEN1, as carcinoma seems to be
an extremely rare event in this condition (32). The
prevalence of parathyroid carcinomas in MEN1 tends to
be much lower than in sporadic cases of HPT (33).
Accordingly, we have seen no cases of parathyroid
carcinoma in our HPT/MEN1 series, compared with higher
frequencies observed in our sporadic HPT cases, in which
we observed a 1.8–6.1% frequency of parathyroid carcinoma
(34,35).
What is the best surgical approach to HPT in MEN1?
The best surgical approach to HPT in MEN1 is under
debate, and includes resection of tissues other than
parathyroid glands themselves.
Preventive thymectomy. Presently, preventive thymec-
tomy is highly recommended to be performed during either
subtotal or total parathyroidectomy in HPT/MEN1 patients.
Since its proposal in 1997 (36), there is a general
agreement that transcervical thymectomy should be per-
formed during parathyroidectomy in all MEN1 cases, in
order to: (a) detect supernumerary parathyroid glands, (b)
prevent thymic carcinoids (occurrence in MEN1 ranges
from 2.6% (37) to 8% (38)), and (c) to disclose intrathymic
parathyroid tissue when less than four parathyroid glands
are identified during neck exploration (39). It has been
estimated that transcervical thymectomy usually excises
only 30–40% of the thymus (39). Consequently, thymic
carcinoids have developed in a few cases, even after
preventive transcervical resection, and this has caused its
value to be questioned (25).
Accordingly, we have adopted routine transcervical
thymectomy during parathyroid intervention in HPT/
MEN1 cases since 1997. To date, no thymic carcinoid has
been detected in the thymic specimens, and none of our
patients has developed thymic carcinoid after this procedure.
However, before 1997, in a specific HPT/MEN1 patient
submitted to parathyroidectomy not associated with trans-
cervical thymectomy, a thymic carcinoid with metastases was
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documented (27). Absence of thymic carcinoid with metas-
tases in prophylactic thymectomy specimens has been
reported in large series by others (30,39).
Subtotal versus total parathyroidectomy. Regarding the
metabolic control of the HPT in MEN1, in the past many
groups have favored more aggressive strategies, such as total
parathyroidectomy followed by immediate parathyroid
autotransplantation (40–43). However, in the last 20 years,
several authors have advocated subtotal parathyroidectomy
as the most suitable strategy in HPT/MEN1 cases (39,44–47).
Currently, only a few authors recommend total parathy-
roidectomy with autotransplantation (30,48–50). In fact,
for many years, it was claimed that only a prospective
randomized trial would help to answer this issue; however,
as far as we know, no such study has been published to date.
Data on this topic vary according to the group, but
subtotal resection seems to be associated with a lesser risk
of hypoparathyroidism. In 57 HPT/MEN1 cases, 34 were
subjected to subtotal parathyroidectomy and 23 to total
parathyroidectomy and autotransplantation. Rates of HPT
persistency or recurrence were higher in the first group,
while post-surgical hypoparathyroidism was more preva-
lent in the second group (51). In a large case series
comprising 92 HPT/MEN1 patients treated over a period
of 42 years, the 10-year actual recurrence-free interval data
were 49% for subtotal parathyroidectomy and 84% for total
parathyroidectomy and autotransplantation (47). In that
series, post-surgical hypoparathyroidism rates were 26% for
subtotal parathyroidectomy and 46% for total parathyroi-
dectomy, but no significant difference was documented
(p= 0.18). Notwithstanding, it was concluded that the high
incidence of severe hypoparathyroidism after total para-
thyroidectomy with autotransplantation favored subtotal
resection as the procedure of choice at the initial operation.
It is worthwhile noting that a limited number of cases
(n= 16) underwent total parathyroidectomy and parathyr-
oid autotransplantation in that study (47). However, in
another recent HPT/MEN1 series (n= 47), patients sub-
mitted to total parathyroidectomy and immediate auto-
transplantation presented with 22% postsurgical permanent
hypoparathyroidism, whereas this rate was 45% in cases
submitted to subtotal parathyroidectomy (30).
The rate of permanent hypoparathyroidism may be
different in patients undergoing a first cervical exploration
or a secondary cervical surgery. Thus, Tonelli et al. observed
hypoparathyroidism in 10 out of 45 patients (22%) after the
first surgery and in three out of six patients (50%) after a
second cervical operation (48). Also, the rate of postsurgical
hypoparathyroidism may be affected by the time of follow–up
of the patient. Accordingly, there are reports of cryopreserved
autografted parathyroid tissues achieving adequate PTH
secretion only 2–4 years after implantation (45).
A recent meta-analysis suggested that subtotal parathyr-
oidectomy is superior to total parathyroidectomy with
immediate autotransplantation (52). Conversely, other authors
favor a more aggressive initial operation (50,53). In this
context, it has been claimed that further high-quality evidence
for the best surgical approach for HPT in MEN1 is lacking.
Experience from a single academic center
In our experience, surgical treatment of HPT in MEN1 is a
highly complex procedure, and the medical residents in our
institution have been trained intensively in this technique
(54,55). Despite improvements in imaging techniques and
intraoperative PTH sampling, the skillfulness of the surgeon
is crucial. Therefore, parathyroidectomy in MEN1 patients
is usually performed to a better standard in specialized
tertiary academic centers where medical personnel and
residents are highly trained (55,56). Moreover, it is also
important that MEN1 patients can be followed-up in
specialized outpatient services in order to receive support
for both oncological and end-organ diseases (43,45,47,48,51,
57–59).
Case series. From 1987 to August, 2011, 83 HPT/MEN1
patients were submitted to 99 parathyroid interventions at
the Hospital das Clı´nicas, University of Sa˜o Paulo School of
Medicine. There were 43 females and 40 males and the age
at the parathyroid surgery varied from 17 to 74 years old
(mean, 40.8 years). No difference in age distribution
according to gender was noticed, as shown in Figure 1.
Almost 75% of the patients were younger than 50 years of
age and this finding may be related to the criteria used to
indicate parathyroidectomy for these patients. In this HPT/
MEN1 series, no child carrying the MEN1 gene had an
indication for parathyroidectomy, although young HPT
cases have been operated on in our group for other reasons,
such as neonatal HPT (60).
Figure 2 shows that there has been an increasing number
of HPT/MEN1 patients in recent years, most probably due
to the active clinical and biochemical search for MEN1
diagnosis, as well as to the routine familial genetic MEN1
screening procedure performed by our group (3,6,7,10,11,
28,61). In a recent study, HPT/MEN1 accounted for 17% of
all cases undergoing parathyroidectomy at our institution
(62).
Seventy-five out of the 83 cases of HPT/MEN1 (90.4%)
had their initial operation at our institution between 1987
and 2011. Of the other eight cases, two underwent
Figure 1 - Age distribution according to gender in 83 cases of
hyperparathyroidism/multiple endocrine neoplasia type 1.
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parathyroidectomy in our institution before 1987 and data
from their first operation are unavailable. Surgeons initially
involved in treating these two HPT/MEN1 cases might
have been unaware of MEN1 at the time, excising only
enlarged parathyroid glands. The remaining six cases
underwent parathyroidectomy in other institutions, and
their previous medical records were not available (Figures 3
and 4).
We had a reoperative rate due to HPT persistence of
8.0% (6/75) and an HPT recurrence rate of 6.75% (5/75),
including all cases. However, taking into account only those
patients with more than 5 years of follow-up (i.e., patients
operated on up to 2006), the gross recurrence rate was 10.6%
(5/47). This latter rate may in fact be slightly higher because
a longer period of follow-up could not be performed in a
few cases.
Total parathyroidectomy and autograft. The standard
initial operation for HPT/MEN1 cases at our institution has
been total parathyroidectomy followed by immediate para-
thyroid autograft to the non-dominant forearm, associated
with transcervical thymectomy. Of note, although other
groups have abandoned cryopreservation of parathyroid
fragments because of the good results obtained with subtotal
parathyroidectomy (46), we continue to advise cryopre-
servation whenever this procedure is possible. Parathyroid
cryopreservation may have some limiting factors (63), but it is
recommended when available, irrespective of the type of
parathyroid surgery, since subtotal resection involves also a
significant risk of permanent hypoparathyroidism (24,30).
Our experience with long-term cryopreserved tissue in
secondary HPT (64) is similar to that reported by others in
MEN1/HPT (30).
Initially, parathyroid autografts consisted of 20 fragments
(each fragment was approximately 261 mm) that were
transplanted in individual pockets. Presently, based in our
experience in secondary HPT, 30 parathyroid gland frag-
ments are usually implanted in a single pocket (65).
Intra-operative PTH. Intra-operative parathyroid hormone
(ioPTH) measurements have been obtained in more recent
cases, although in our protocol all glands should be searched
and excised irrespective of their macroscopic appearance. In
our experience, ioPTH in HPT/MEN1 cases has presented
some limitations. Indeed, preoperative diagnosis of MEN1 is
much more informative to the surgeon than imaging studies
Figure 2 - Emerging recognition and surgical treatment of
patients with hyperparathyroidism/multiple endocrine neoplasia
type 1 at our institution.
Figure 3 - Distribution of patients with hyperparathyroidism/multiple endocrine neoplasia type 1 who had not had a previous neck
operation (1987 to 2011).
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or ioPTH. Thus, it can inform: (a) whether additional high
hyperfunctional parathyroid tissue was left behind (which
has not happened yet in our group); or (b) whether the
exploration can be finished, despite the fact that fewer than
four glands have been identified after an extensive search.
For academic purposes, we usually measure PTH at the
following times: at the induction of anesthesia (basal), after
identification of all parathyroid tissue (pre-excision), 10 min
after the resection of the largest parathyroid gland, and
again 10 min and 15 min after the excision of the remaining
parathyroid tissue and thymus. In some circumstances, a
decrease .50% of ioPTH has been observed after the
excision of the largest parathyroid gland (Figure 5). This
finding has been described previously (66), and may explain
failures of ioPTH in the surgical management of HPT/
MEN1 patients (31).
Reoperations by the same team. Fourteen out of the 75
HPT patients (18.7%) were reoperated in a total number
of 16 reoperative procedures (Figure 3). Not all neck
reoperations were related to HPT. Two consisted of
total thyroidectomy and neck dissection for associated
metastatic papillary thyroid carcinoma. In five cases, the
parathyroid autograft at the forearm was excised due to
recurrent HPT. One patient with non-functioning tumors
was operated on due to goiter, and recurrence occurred
later (see details of this case below). In five cases (6.7%),
fewer than four glands could be initially identified at the
first operation, and early HPT recurrence or persistence was
observed: two retropharyngeal right superior parathyroid
glands (one patient with right thyroid lobe agenesia), one
intrathyroidal gland, one superior gland, and one located at
the aortic arch in medium mediastinum and excised by
thoracoscopy. Two further cases presented with late HPT
recurrence due supernumerary parathyroid glands. One
was located at the cervical region and the other at the
mediastinum and, in this latter case, total thymectomy was
performed by sternotomy. A rate as high as 33% for
supernumerary glands has been reported in MEN1/HPT
cases, including intrathyroidal supernumerary glands in
2.5% of patients (8). In our current experience, no patient
with MEN1/HPT has presented a supernumerary intrathy-
roidal gland; however, it has been observed in some patients
with renal HPT at our center (67). Our rate of intrathymic
supernumerary glands was 4.9% (unpublished data). This
rate is rather inferior to the rate of almost 30% reported by
others (8). However, in a large series of routine bilateral
cervical thymectomy in renal HPT, the frequency of super-
numerary thymic parathyroids was 6.5% (68). A similar rate
of 6% has been described in MEN1/HPT (39).
Of note, two specific cases were called our attention, and
they are commented on below.
Non-functional tumor progression. The first case of non-
functional tumor progression was a female patient who was
initially submitted to cervical surgery in 1993 and presented
MEN1-related tumors: a non-functioning pituitary adenoma,
multiple pancreatic endocrine tumors, as well as a goiter. No
Figure 4 - Distribution of patients with hyperparathyroidism/multiple endocrine neoplasia type 1 who had had a previous neck
operation.
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calcium abnormality was present at that time. During the
partial thyroidectomy (lobectomy), an enlarged parathyroid
was excised, although total parathyroidectomy was not
performed at that time. She had no evidence of HPT until
13 years after parathyroid adenomectomy, when HPT ensued
and she was subjected to reoperation. This case illustrates
that hyperparathyroidism may ensue many years after an
apparent non-functional enlargement of the para-
thyroid gland.
Relative of a MEN1 patient, with HPT due to a
phenocopy. Another case, not included in the present
series, is a person with HPT who was a relative of a MEN1
patient. This case came to the hospital with a clinical diagnosis
of HPT/MEN1. However, after sequencing allMEN1 and p27
exons and their boundaries, no germline mutations were
found characterizing a phenocopy, as previously reported in
this condition (69). Thus, the surgical choice for this specific
patient was a single parathyroid resection, with resolution of
HPT. The patient is still under observation, without any sign
of recurrence five years after the operation.
Reoperations from other centers. As mentioned, six of
our HPT/MEN1 cases were initially operated on in other
centers. Two were previously subjected to total thyroidectomy
due to papillary thyroid carcinoma; a simultaneous intra-
operative single parathyroid adenoma was found by the first
surgeon. The two reoperations involved resection of the three
additional parathyroid glands, central neck dissection and
thymectomy. The third patient had been subjected to an
intentional subtotal parathyroidectomy due to HPT/MEN1 at
his primary center seven years before. His remnant was
excised and partially autografted.
Three other cases had been subjected previously to
surgery due to ‘‘a parathyroid adenoma’’; in these cases,
excision of the remaining parathyroid glands was carried
out, followed by parathyroid autografts and thymectomy in
one of the patients. One of these patients had been
previously subjected to two cervical surgical explorations
in another center; however, HPT persisted due an undes-
cended left inferior parathyroid gland located close to the
submandibular gland. This residual gland was discovered
after a careful review of sestamibi scintigraphy. A first quick
view may be misinterpreted as a negative result in planar
projection (Figure 6). We excised this remaining parathyroid
gland and part of it was immediately auto-implanted to the
non-dominant forearm.
Thyroid cancer in MEN1/HPT. Papillary thyroid
carcinoma was found in five out of 83 cases (6%). This
frequency was similar to that observed in sporadic HPT cases
(9%) and carcinomas incidentally found in compressive
multinodular goiter (11%) treated at the same institution
(70). In four out of five cases, pathological data were
available: all cases had microcarcinomas, which were
multicentric in two instances. Microscopic metastases were
present in two cases, and one had unilateral neck lymph node
metastasis. One of these patients had apparently been
subjected to high-dose radiotherapy due to a pituitary
tumor many years before the neck operation.
Recurrence and hypoparathyroidism. Recently, we
attempted to contact 71 out of the 85 patients operated on
from 1987 to 2010 in our institution, and information of 45
Figure 6 - Sestamibi scintigraphy after two previous neck
interventions in a patient with hyperparathyroidism/multiple
endocrine neoplasia type 1 who had been treated initially at
another hospital. There was a focal radiopharmacological
concentration close to the left submandibular gland due to an
undescended left inferior parathyroid.
Figure 7 - Numbers (%) of patients with hyperparathyroidism/
multiple endocrine neoplasia type 1 requiring calcium supple-
ments according to time elapsed since the initial treatment (1998
to 2010).
Figure 5 - A marked decrease of intra-operative parathyroid
hormone (ioPTH) after excision of the largest parathyroid gland
only, in a case of hyperparathyroidism/multiple endocrine
neoplasia type 1. Persistence or early hyperparathyroidism
recurrence may occur if surgery is guided solely by ioPTH.
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was available. As a first approach, a compact questionnaire
was given to these patients in order to update the
information on post-surgical therapy with the calcium
supplement. Ten out of the 45 patients had died because
of neoplasias other than MEN1-related tumors (22.2%). This
observation might serve to re-emphasize the importance of
early MEN1 detection and treatment, with the aim of
decreasing morbidity and mortality, with reference to
MEN1-related tumors in MEN1 (3). Five out of the 35
remaining cases (14.3%) had recurrent HPT disease; 14
others (40.0%) required calcium and/or calcitriol
replacement therapy; and the remaining 16 cases did not
take either calcium or calcitriol (45.7%). It is worthwhile
noting that in HPT/MEN1 cases calcium requirement rates
are impacted by the time elapsed since the
parathyroidectomy. In Figure 7, the percentages of
patients requiring calcium supplements were obtained at
different periods after parathyroid intervention. We found
that the longer the follow-up, the lower the frequency of
patients requiring calcium supplement. Accordingly, in one
of our HPT/MEN1 series, parathyroid auto-implants took
from 6 to 15 months to secrete sufficient amounts of PTH in
order to lead to normal calcemia (58).
For each individual HPT/MEN1 patient, it is necessary to
decide which is the best operation to achieve the ultimate
goal of maintaining normocalcemia and avoiding both
iatrogenic hypocalcemia and operative complications; and
facilitating future surgery for recurrent disease (71,72).
In many cases, calcium/calcitriol supplemental therapy
could be stopped 15 months after total parathyroidectomy
followed by parathyroid auto-implant, but not in all patients
(58). A question to be addressed is the amount of calcium
supplement required for each case. In our patients taking
calcium supplement for more than one year, the mean
intake was 1.6 g/day (range, 0.5–3.0 g/day), and 50% were
taking 1.5 g/day or less.
Our present observations are in accordance with others:
parathyroid autografts may take long periods, sometimes
up to seven years, to achieve adequate function, and PTH
levels increase with time (23,58).
Subtotal and total parathyroidectomy followed by
immediate parathyroid autotransplantation are surgical
approaches that are currently accepted to treat cases with
HPT associated with MEN1. In our single academic center,
total parathyroidectomy followed by parathyroid auto-
transplantation to the non-dominant forearm associated
with preventive transcervical thymectomy has been the
surgical approach of choice for cases of HPT/MEN1. This
strategy has been successful in achieving low rates of HPT
recurrence. The considerable number of calcium-depen-
dent patients, who were mainly observed in the first nine
months after operation, tended to decrease during long-
term follow-up.
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